Loading...
XLON
COG
Market cap19mUSD
Jul 09, Last price  
31.50GBP
1D
-5.97%
1Q
-19.23%
Jan 2017
-54.35%
IPO
-62.28%
Name

Cambridge Cognition Holdings PLC

Chart & Performance

D1W1MN
XLON:COG chart
P/E
P/S
1.56
EPS
Div Yield, %
Shrs. gr., 5y
7.81%
Rev. gr., 5y
6.88%
Revenues
9m
-9.11%
4,828,3545,579,6575,683,6404,148,0005,802,0005,042,0006,876,0006,730,0006,134,0005,042,0006,741,00010,094,00012,613,00013,515,00010,342,0009,400,000
Net income
-2m
L-6.16%
719,610-160,725-1,576,024-2,861,000-173,000-782,000272,000-257,000-1,442,000-2,901,000-438,000450,000-409,000-3,508,000-1,785,000-1,675,000
CFO
-232k
L-92.48%
550,161535,213-700,746-2,472,000-693,000-708,000473,000-624,000-644,000-2,315,0001,014,0003,934,0001,677,000-4,967,000-3,085,000-232,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
IPO date
Apr 18, 2013
Employees
80
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT